Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Illinois Man Denies Cancer Drug Smuggling Conspiracy

By Drug Discovery Trends Editor | August 27, 2015

An Illinois man pleaded not guilty Tuesday to conspiring with an online Canadian pharmacy to smuggle mislabeled, unapproved and, in two cases, counterfeit prescription drugs into the U.S. to sell to doctors.

Ram Kamath appeared before U.S. Magistrate Judge Jeremiah Lynch for arraignment in Missoula. So far, he is the only one of the 14 individuals and companies named as defendants to appear in court to face criminal smuggling, conspiracy and money laundering charges.

Federal prosecutors accuse Canadadrugs.com, its CEO Kristjan Thorkelson and its affiliated companies and associates of selling $78 million in prescription drugs, primarily cancer treatment drugs, to U.S. doctors. Nearly all of the drugs are legal in the U.S. when sold by FDA-approved manufacturers and marketers.

Prosecutors said some of the drugs were mislabeled by having text in a foreign language or missing the required “Rx only” symbol. Others, such as the Turkish drug Altuzan, are not approved by the Federal Drug Administration. Two types of cancer treatment drugs turned out to be counterfeit versions, according to the indictment.

“Canada Drugs purchased its inventory from questionable sources and ultimately sold counterfeit versions of the drugs Altuzan and Avastin to physicians in the United States,” the indictment read.

Federal prosecutors will seek to extradite Thorkelson and the other defendants from Canada, the United Kingdom and Barbados if they do not voluntarily appear, according to court documents.

Assistant U.S. Attorney Chad Spraker, defense attorney Michael Sherwood and a Canadadrugs.com spokesman did not return calls for comment.

The 14-year-old Winnipeg company’s website describes itself as offering low prices on medicine from Canada, the U.K., Australia and New Zealand.

In 2009 and 2010, Canadadrugs.com bought companies – including Montana Healthcare Solutions – that sold pharmaceuticals directly to U.S. doctors. Using those companies’ customer lists, Canadadrugs.com began selling to doctors by shipping drugs from its U.K. subsidiary, according to the indictment.

The subsidiary, River East Supplies, falsified customs labels to undervalue the packages’ contents in an attempt to avoid scrutiny of the shipments, federal prosecutors said. The drugs would go to unnamed companies in Illinois, Washington state and Tennessee for storage and distribution.

When the company discovered the counterfeit drugs, it tried to conceal the problem by asking Kamath to store some in his Downers Grove, Illinois, home while the company scrambled to recall them to the U.K.

Kamath was director of pharmacy policy and international verifications for an unnamed company, for which he inspected storage facilities kept by Internet pharmacies. The online pharmacies funneled cash to Kamath’s company and paid for a trip to Barbados with four-star accommodations for Kamath to inspect Canadadrugs.com’s facilities there, according to the indictment.

“In exchange, Kamath would help provide them with the veneer of legitimacy that comes with having been inspected by an `independent’ party,” the indictment read.

Kamath did not document in his inspection reports that he stored counterfeit drugs in his garage, prosecutors said. He is charged with one count of conspiracy to smuggle goods into the United States.

Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE